Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib for active ankylosing spondylitis in biologic-naive adults
NL-OMON50247Phase 3Completed
- Sponsor
- Site Management & Monitoring
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing Upadacitinib with Placebo (2 arms). Primary endpoint: ASAS40 response at Week 14. Started Jul 2018; status: completed.
02
Drugs
upadacitinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON50247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50247.